Amassing the Clinical Evidence for Optimized Dyslipidemia Ma - Episode 14

Aggressive LDL Lowering with PCSK9 Inhibition

%jwplayer%

The MD Magazine Peer Exchange “Amassing the Clinical Evidence for Optimized Dyslipidemia Management: Vitamin D, Long-Term Statin Outcomes, and PCSK9 Inhibition” features expert insight and analysis of the latest information on managing hypertension and hyperlipidemia, and in-depth discussion on the use of PCSK9 inhibitors in practice.

This Peer Exchange is moderated by Peter Salgo, MD, professor of medicine and anesthesiology at Columbia University and an associate director of surgical intensive care at the New York-Presbyterian Hospital in New York City.

The panelists are:

  • Christie Ballantyne, MD, Co-director of the Lipid Metabolism and Atherosclerosis Clinic at The Methodist Hospital, Director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart Center, and the Chief of Cardiology at Baylor College of Medicine
  • Keith C. Ferdinand, MD, Immediate Past Chair of the National Forum for Heart Disease and Stroke Prevention, and Professor of Clinical Medicine at the Heart and Vascular Institute at Tulane University School of Medicine
  • Jennifer G. Robinson, MD, MPH, Professor in the Departments of Epidemiology & Medicine and Director of the Prevention Intervention Center, Department of Epidemiology at the College of Public Health, University of Iowa
  • Karol E. Watson, MD, PhD, Professor of Medicine and Cardiology, Co-director of the UCLA Program in Preventive Cardiology, and Director of the UCLA Barbra Streisand Women’s Heart Health Program

The panel explained the findings of the ODYSSEY Alternative trial in patients with statin intolerance. What it showed was dramatic LDL reduction with a PCSK9 inhibitor plus ezetimibe compared with statin therapy. And the LDL lowering is even more pronounced when a PCSK9 inhibitor is taken with a statin, said Robinson, calling PCSK9 inhibition “a big hammer.”

Despite the impressive efficacy, Watson and Ferdinand urged caution in terms of safety, because it is still too early to see long-term effects, although Ballantyne said that the similar discontinuation rates in the groups were encouraging.